Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study | Zendy

Khalid Jadoon | Zendy; S. Ratcliffe | Zendy; David A. Barrett | Zendy; E. Louise Thomas | Zendy; Colin Stott | Zendy; Jimmy D. Bell | Zendy; Saoirse E. O’Sullivan | Zendy; Garry D. Tan | Zendy

Open Access

Efficacy and Safety of Cannabidiol and Tetrahydrocannabivarin on Glycemic and Lipid Parameters in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Pilot Study

Author(s) -

Khalid Jadoon,

S. Ratcliffe,

David A. Barrett,

E. Louise Thomas,

Colin Stott,

Jimmy D. Bell,

Saoirse E. O’Sullivan,

Garry D. Tan

Publication year - 2016

Publication title -

diabetes care

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.636

H-Index - 363

eISSN - 1935-5548

pISSN - 0149-5992

DOI - 10.2337/dc16-0650

Subject(s) - medicine , endocrinology , type 2 diabetes , adiponectin , lipid profile , glycemic , placebo , insulin resistance , insulin , diabetes mellitus , alternative medicine , pathology

Cannabidiol (CBD) and Δ(9)-tetrahydrocannabivarin (THCV) are nonpsychoactive phytocannabinoids affecting lipid and glucose metabolism in animal models. This study set out to examine the effects of these compounds in patients with type 2 diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research